In December 2011, CIP VI acquired 100% of Crédit Agricole Private Equity (CAPE) and the majority of the underlying funds that CAPE manages.
Strategy: Private capital
Lloyds Banking Group
In July 2010, CIP VI, formed a joint venture with Lloyds Banking Group to acquire a £480m portfolio from the bank.
3i
In September 2009, CIP V, purchased the majority of 3i’s remaining venture portfolio of technology and life sciences companies alongside HarbourVest Partners and DFJ Esprit. Coller Capital won Venture Capital Deal of the Year, 2009 for this transaction.
SVG Capital plc
In February 2009, CIP V participated in an innovative rights issue and share placement by SVG Capital plc – the major investor in Permira buyout funds. Through this rights issue, CIP V acquired a 20% stake in the business.
Pearl Diver Capital
In November 2008, the first commitment was made to a series of CLO porfolios across CIP V, CIP VI and CIP VII funds.
Royal Dutch Shell
In March 2007, CIP V established a $1bn joint venture with Shell to develop a portfolio of 34 investments. The joint venture structure enables Shell to maintain its existing strategic links with the portfolio companies, whilst benefiting from Coller Capital’s expertise and resources as a financial investor.
ABN AMRO
In December 2006, CIP IV formed a €193m joint venture with ABN AMRO Capital. Forbion Capital Partners span out of the bank to manage the portfolio of 26 life science companies.
ICICI Venture
In January 2006, CIP IV invested in ICICI Venture’s India Advantage Fund I – India’s first secondaries transaction. Coller’s proposals were tailored to meet the needs of individual sellers.
Dresdner Kleinwort Benson
In September 2004, CIP IV acquired a $90 million portfolio of companies from Dresdner Kleinwort Benson.
Abbey
In January 2004, CIP IV closed another landmark secondaries investment – the acquisition of a $900 million portfolio from Abbey bank (now part of Banco Santander). The deal involved 41 fund positions, 32 different managers, 16 direct investments, and around 850 underlying companies. The transaction was, at the time, the largest secondaries investment by a single firm.